Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.74 |
| ▸ | CDK7 | P50613 | 1/20 | 0.62 |
| ▸ | CDK9 | P50750 | 1/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | INSR | P06213 | 1/20 | 0.59 |
| ▸ | IGF1R | P08069 | 1/20 | 0.59 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.59 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.59 |
| ▸ | MET | P08581 | 3/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1203252 | 0.88 | ULK1 (0.59) | ULK1CDK7CDK9PTK2MAPK8 | |
| SCHEMBL375665 | 0.87 | ULK1 (0.58) | ULK1CDK7CDK9PTK2MAPK8 | |
| SCHEMBL16385440 | 0.87 | ULK1 (0.58) | ULK1CDK7CDK9PTK2MAPK8 | |
| SCHEMBL1203432 | 0.87 | ULK1 (0.58) | ULK1CDK7CDK9PTK2MAPK8 | |
| SCHEMBL30500640 | 0.87 | ULK1 (0.74) | ULK1CDK7CDK9PTK2MAPK8 | |
| SCHEMBL29900878 | 0.87 | ULK1 (0.58) | ULK1CDK7CDK9PTK2MAPK8 | |
| SCHEMBL30086235 | 0.87 | ULK1 (0.58) | ULK1CDK7CDK9PTK2MAPK8 | |
| SCHEMBL12311805 | 0.87 | ULK1 (0.82) | ULK1CDK7CDK9PTK2MAPK8 | |
| SCHEMBL12627646 | 0.87 | ULK1 (0.58) | ULK1CDK7CDK9PTK2MAPK8 | |
| SCHEMBL2061282 | 0.86 | ULK1 (0.56) | ULK1CDK7CDK9PTK2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878468-B | Diamino pyrimidine compound containing phenyl nitrogen mustard fragment and preparation method and application thereof | 贵州大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-118878468-A | Diamino pyrimidine compound containing phenyl nitrogen mustard fragment and preparation method and application thereof | 贵州大学 | 2024-11-01 | — | — | CN | disclosed |
| CN-118772116-A | 2, 4-Diaryl aminopyrimidine compound and preparation method and application thereof | 南通常佑药业科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118063393-A | 2, 4-Diaminopyrimidine derivative and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-05-24 | — | — | CN | disclosed |
| WO-2024022244-A1 | HETEROCYCLIC COMPOUND HAVING BIOLOGICAL ACTIVITY | 首药控股(北京)股份有限公司 | 2024-02-01 | — | — | WO | disclosed |
| CN-116969897-A | Sulfonamide compound, preparation method and application thereof, and pharmaceutical composition | 北京大学 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023109751-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | 希格生科（深圳）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023088385-A1 | COMPOUND FOR DEGRADING EGFR PROTEIN AND USE THEREOF | 浙江同源康医药股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | Sanford Burnham Prebys Medical Discovery Institute | 2023-05-04 | — | — | US | disclosed |
| CN-115515589-A | ULK1/2 inhibitors and methods of use thereof | 萨克生物研究学院 | 2022-12-23 | — | — | CN | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1784392-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | disclosed |
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1660458-A1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | Novartis AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006021454-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | disclosed |
| EP-1606265-A1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | Novartis AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| WO-2005016894-A1 | 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004080980-A1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135635-A1 | INHIBITORS OF ULK1/2 AND METHODS OF USING SAME | ULK2, ULK1, ULK3 | ULK1 2/4885CDK7 872/4885CDK9 836/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | ULK1 2458/4885CDK7 284/4885CDK9 379/4885 |
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | TYMS, UMPS, TYMP | ULK1 2014/4885CDK7 343/4885CDK9 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.